MediWound addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel. Hospitals and military forces have urgently requested NexoBrid supplies. To address this critical need, MediWound has deployed all its available NexoBrid inventory to aid the substantial number of burn victims.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDWD:
- MediWound Deploys NexoBrid® for Emergency Supply
- MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
- MediWound secures additional U.S. DoD funding of $6.5M to advance NexoBrid
- MediWound price target raised to $26 from $23 at H.C. Wainwright
- MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults